Slow buy-in: Only 3% of neurologists have written Aduhelm prescriptions so far
By
Alicia Lasek
Jul 15, 2021
Neurologists are very aware of Biogen’s newly approved Alzheimer’s drug, but few have prescribed it so far, a real-time study of the brand’s market launch has found.
MS drug Tecfidera approved, awaited
By
Kevin McCaffrey
May 01, 2013
The approval of Biogen Idec’s MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by WorldOne...
Criticism, confusion and hope: new Alzheimer’s drug receives messy welcome
By
Alicia Lasek
Jun 15, 2021
Clinicians’ responses to the controversial approval of Aduhelm range between excitement and disapproval, with questions abounding on how to advise patients on treatment and the cost to patients and...